16S rRNA sequencing of gut microbiota in Tanzanian TB patients and controls

Tuberculosis (TB) and its treatment can disrupt the gut microbiome, potentially affecting immune regulation and treatment outcomes. In this cross-sectional study, we analyzed the gut microbiome profiles of pulmonary TB patients, both newly diagnosed and those who had received two months of anti-TB therapy, compared to healthy controls in Tanzania. Gut microbial composition was assessed using 16S rRNA gene sequencing on the Illumina MiSeq platform.